Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Earkart Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
About Earkart Ltd.
| Founded | 2021 |
|---|---|
| Managing Director | Rohit Misra |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,57,121.30 | 1,905.20 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,81,396.01 | 6,818.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,48,729.85 | 4,394.35 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,15,331.11 | 8,028.70 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,240.83 | 1,426.60 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,11,126.23 | 1,329.30 | 1,148.40 - 1,148.40 |
| Mankind Pharma Ltd. | 1,03,056.40 | 2,504.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,03,022.72 | 1,060.00 | 903.00 - 903.00 |
| Lupin Ltd. | 1,03,010.73 | 2,248.00 | 1,836.80 - 1,836.80 |
| Zydus Lifesciences Ltd. | 99,737.91 | 991.20 | 835.50 - 835.50 |
No Records Found
Latest News
EarKart informs about compliances certificate
In compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, EarKart has enclosed the Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the Quarter ended 31 March 2026, received from M/s Skyline Financial Services, the Registrar to an issue and Share Transfer Agent (RTA) of the company.
The above information is a part of company’s filings submitted to BSE.
Earkart informs about board meeting
Pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Earkart has informed that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, 30th March 2026 to consider and approve the following agenda: a. Variation in the Objects/terms of utilization of the Initial Public Offering (‘IPO’) proceeds and extension of time limit for utilization of the IPO proceeds. The same will be made available on the Company's website https://www.earkart.in.
The above information is a part of company’s filings submitted to BSE.
Aarti Drugs informs about newspaper publication
Fortis Malar Hospitals informs about outcome of board meeting
Pursuant to the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 (‘SEBI Listing Regulations’) Fortis Malar Hospitals has informed that the Board of Directors of the Company at its meeting held today, Monday, May 18, 2026, considered and approved the following: - 1. Financial Results: Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026 along with Statement of Assets and Liabilities as on March 31, 2026. B S R & Co. LLP, the Statutory Auditors of the Company have issued an Audit Report with an unmodified opinion on the Standalone and Consolidated Financial Statements. Accordingly, the standalone and consolidated audited financial results, auditors’ reports, Statement of Assets & Liabilities, and declaration pursuant to Regulation 33(3)(d) of the SEBI Listing Regulations, regarding Unmodified Opinion on the Audited financial results for the financial year ended March 31, 2026 are enclosed; 2. Adoption of Policies: a. The modification in the policy for the determination of Materiality of Events/Information, which also contains the details of persons authorized to determine the Materiality of the Event/Information for the purpose of disclosures to Stock Exchange. The said revised policy has been enclosed. b. The updated Policy/Code of Conduct for the prevention of Insider Trading. The said updated policy/Code has also been enclosed. The Board Meeting commenced at 11:30 am (IST) and concluded at 03:35 pm (IST). The same is also uploaded on the website of the Company.
The above information is a part of company’s filings submitted to BSE.
MPS Pharmaa informs about board meeting
Pursuant to Regulation 29 of the Securities and Exchange Board of India (LODR) Regulations, 2015, MPS Pharmaa has informed that as per the requirements of Regulation 33 of the Securities and Exchange Board of India (LODR) Regulations, 2015, a meeting of the Board of Directors of the company is scheduled to be held on Thursday, 28th May, 2026 at 12:00 pm at the corporate office of the company at 703, Arunachal Building, 19, Barakhambha Road, Connaught Place, New Delhi-110001, to transact the following business: 1. To consider and approve the Audited Financial Results of the Company for the quarter and Financial Year ended 31st March, 2026. 2. To consider and approve the Auditors’ Report on the Audited Financial Results of the Company for the quarter and Financial Year ended 31st March, 2026. 3. To consider the appointment of Sanghi & Co., Chartered Accountants as the Internal Auditor of the Company for the F.Y. 2026-27. 4. To carry on any other business with the permission of the Board. Further, pursuant to BSE Circular no. LIST/COMP/01/2019-20 dated April 02, 2019 and in accordance with Code of Conduct for Prevention of Insider Trading framed by the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulation, 2015, the trading window for dealing in the shares of the Company for all Directors/Officers/Designated Employees of the Company and their relatives, is already closed for the purpose of declaration of Audited Financial Results for the quarter and Financial Year ended 31st March, 2026. Accordingly, the trading window of the company shall remain closed till 30th May, 2026.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Earkart Ltd. is ₹126.80 as of 2026-05-18.
The market capitalisation of Earkart Ltd. is ₹174.40 as of 2026-05-18.
The 1-year return of Earkart Ltd. is % as of .
The P/E ratio of Earkart Ltd. is 0.00 as of 2026-05-19.
The 52-week high and low of Earkart Ltd. are ₹265.95 and ₹114.50, respectively, as of 2026-05-18.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
